Real-World Evidence 2022: Rare Diseases and Innovative Therapies

by Stephen Riddle

Real-World Evidence 2022: Rare Diseases and Innovative Therapies (RWE 2022) will convene the full spectrum of stakeholders working in RWE in rare diseases and innovative therapies, including pharma and biotech, medical device companies, health technology assessors (HTAs), regulators, payers, academics, patient advocacy groups and service providers – to discuss how we accelerate RWE and regulatory approval in a post-COVID and post-Brexit world.

Our mission is to convene a community of collaboration and best practice around the practical application of RWE in rare diseases and innovative therapies, so the event will bring together exciting formats to encourage conversation, collaboration and action. We’ll have panels, presentations and discussions to collaborate and master best practices in RWE, alongside roundtables and fishbowl conversations to create an open approach to collaboratively accelerate new ideas and innovation.


What will be discussed?

Take a look at our agenda page for the latest updates on the program. Core themes will include:

  • Reimbursement and payer models
  • Regulatory tools and fairness
  • The impact of big data, artificial intelligence and machine learning
  • Exploring quality, registries and patient-first practices

[ui-btn url=”″ text=”BOOK YOUR PLACE” target=”_blank”][/ui-btn]


 Earlybird pricing (ends 11 April 2022) Standard pricing (ends 29 June 2022) 
Standard registration £1200 (£1440 inc. VAT) £1500 (£1800 inc. VAT) 
Pharma/biotech registration £800 (£960 inc. VAT) £1000 (£1200 inc. VAT) 
Academic/public sector registration £300 (£360 inc. VAT) £400 (£480 inc. VAT)  


If you are a patient or patient advocate, or work in another sector that may be entitled to a discounted or free ticket, please email us directly at [email protected] to let us know

Got a question? Contact the RWE 2022 team via [email protected] 

This post was originally published on Source Link

You may also like